查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552893

糖尿病相关眼部保健市场规模、份额和趋势分析报告：按应用、类型、最终用途、地区、细分市场预测，2024-2030

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

糖尿病相关眼保健市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，到 2030 年，全球糖尿病相关眼部保健市场规模预计将达到 513.3 亿美元，2024 年至 2030 年复合年增长率为 6.9%。

II 型糖尿病盛行率的增加、老年人口的增加以及早期检测技术的可用性是推动成长的一些因素。再加上对技术进步和早期诊断的认识不断提高，有助于提高现有治疗方案的成功率。评估用于预防和管理这些眼科疾病的新药和设备的临床试验数量不断增加，预计将在未来几年推动市场成长。

与 COVID-19 相关的糖尿病和眼科併发症预计将推动糖尿病相关眼科治疗方法市场的发展。 COVID-19 对糖尿病有长期影响。因此，预计未来几年对治疗方法的需求将会增加。政府和非营利组织加强提高人们对糖尿病相关眼疾的认识，预计将推动治疗设备的采用。此外，世卫组织和以色列国防军正在共同努力，透过提供便利的治疗设施来预防和管理糖尿病，并改善世界各地人们的生活品质。

糖尿病相关眼保健市场报告亮点：

  • 到 2023 年，糖尿病视网膜病变领域将占据最大的收益占有率，其次是糖尿病相关的黄斑部病变和青光眼。
  • 由于全球市场存在主要企业、渗透率高以及开发创新药物的临床试验数量不断增加等因素，药品细分市场将在2023年占据市场主导地位并收益占有率。
  • 与其他医疗机构相比，由于患者就诊数量不断增加以及医院基础设施先进，预计医院行业在预测期内将呈现最快的增长速度。糖尿病住院人数的增加正在推动需求并推动该领域的成长。
  • 北美地区占据市场最大的收益占有率，预计在收益预测期内将保持其主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 糖尿病相关眼部保健市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 糖尿病相关眼部保健市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 糖尿病相关眼科治疗市场：按应用估计与趋势分析

  • 细分仪表板
  • 糖尿病相关眼部保健市场：2023 年和 2030 年应用变化分析
  • 干眼症
    • 2018-2030 年收益估计与预测
  • 青光眼
    • 2018-2030 年收益估计与预测
  • 眼睛过敏和感染疾病
    • 2018-2030 年收益估计与预测
  • 糖尿病视网膜病变
    • 2018-2030 年收益估计与预测
  • 糖尿病黄斑部病变
    • 2018-2030 年收益估计与预测
  • 葡萄膜炎
    • 2018-2030 年收益估计与预测
  • 白内障
    • 2018-2030 年收益估计与预测
  • 糖尿病黄斑部水肿
    • 2018-2030 年收益估计与预测
  • 其他的
    • 2018-2030 年收益估计与预测

第五章 糖尿病相关眼科治疗市场：按类型估计和趋势分析

  • 细分仪表板
  • 糖尿病相关眼科治疗市场：类型分析，2023 年和 2030 年
  • 药品
  • 装置

第六章 糖尿病相关眼科治疗市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 糖尿病相关眼部治疗市场：最终用途和趋势分析，2023 年和 2030 年
  • 医院
  • 眼科中心
  • 门诊中心
  • 其他的

第七章 糖尿病相关眼科治疗市场：区域估计与趋势分析

  • 2023 年及 2030 年糖尿病相关眼保健市场占有率（按地区）
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Alcon
    • Johnson &Johnson Services, Inc.
    • Bausch Health
    • F. Hoffmann-La Roche Ltd
    • Allergan
    • Bayer AG
    • Santen Pharmaceutical Co. Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Genentech, Inc.
    • Carl Zeiss Meditec
    • Lumenis
    • Ellex Medical Lasers Ltd.
    • IRIDEX Corp.
    • Topcon Corp.
    • Abbott Medical Optics
    • Quantel
简介目录
Product Code: GVR-4-68039-553-5

Diabetes Associated Ophthalmic Treatment Market Growth & Trends:

The global diabetes associated ophthalmic treatment market size is expected to reach USD 51.33 billion by 2030, registering to grow at a CAGR of 6.9% from 2024 to 2030 according to a new report by Grand View Research, Inc. The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.

COVID-19 related diabetic and ophthalmic complications are expected to boost the market for diabetes associated ophthalmic treatment methods. COVID-19 has a long-term effect on diabetic conditions. This is expected to increase the demand for treatment procedures in upcoming years. An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.

Diabetes Associated Ophthalmic Treatment Market Report Highlights:

  • The diabetic retinopathy segment has captured the largest revenue share in 2023 followed by diabetic associated macular degeneration and glaucoma
  • The drugs segment dominated the market and accounted for the highest revenue share in 2023 owing to factors such as the presence of major key players operating in the global market, high adoption rate, increased clinical trials to develop innovative drugs
  • The hospitals segment is predicted to witness the fastest growth rate over the forecast timeframe due to the increasing number of patient visits and advanced infrastructure in hospitals as compared to other healthcare facilities. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment, thereby propelling the growth
  • North America held the largest revenue share in the market and is expected to maintain its dominance over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. The Diabetes Associated Ophthalmic Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. The Diabetes Associated Ophthalmic Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Diabetes Associated Ophthalmic Treatment Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Diabetes Associated Ophthalmic Treatment Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Dry Eye Syndrome
    • 4.3.1. Dry Eye Syndrome Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Glaucoma
    • 4.4.1. Glaucoma Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Eye Allergy & Infection
    • 4.5.1. Eye Allergy & Infection Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Diabetic Retinopathy
    • 4.6.1. Diabetic Retinopathy Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Diabetic associated Macular Degeneration
    • 4.7.1. Diabetic associated Macular Degeneration Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Uveitis
    • 4.8.1. Uveitis Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Cataract
    • 4.9.1. Cataract Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Diabetic Macular Edema
    • 4.10.1. Diabetic Macular Edema Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Associated Ophthalmic Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Diabetes Associated Ophthalmic Treatment Market: Type Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Drugs
    • 5.3.1. Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Devices
    • 5.4.1. Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Diabetes Associated Ophthalmic Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Diabetes Associated Ophthalmic Treatment Market: End Use & Trend Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ophthalmic Centres
    • 6.4.1. Ophthalmic Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Ambulatory Centres
    • 6.5.1. Ambulatory Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Diabetes Associated Ophthalmic Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Diabetes Associated Ophthalmic Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. Europe
    • 7.2.1. UK Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. Germany
      • 7.2.2.1. Germany Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. France
      • 7.2.3.1. France Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Italy
      • 7.2.4.1. Italy Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5. Spain
      • 7.2.5.1. Spain Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6. Denmark
      • 7.2.6.1. Denmark Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7. Sweden
      • 7.2.7.1. Sweden Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8. Norway
      • 7.2.8.1. Norway Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Middle East and Africa
    • 7.3.1. South Africa Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Saudi Arabia
      • 7.3.2.1. Saudi Arabia Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. UAE
      • 7.3.3.1. UAE Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Kuwait
      • 7.3.4.1. Kuwait Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Alcon
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Bausch Health
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Allergan
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Santen Pharmaceutical Co. Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Novartis AG
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Genentech, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Carl Zeiss Meditec
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Lumenis
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. Ellex Medical Lasers Ltd.
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. IRIDEX Corp.
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives
    • 8.4.15. Topcon Corp.
      • 8.4.15.1. Participant's Overview
      • 8.4.15.2. Financial Performance
      • 8.4.15.3. Product Benchmarking
      • 8.4.15.4. Recent Developments/ Strategic Initiatives
    • 8.4.16. Abbott Medical Optics
      • 8.4.16.1. Participant's Overview
      • 8.4.16.2. Financial Performance
      • 8.4.16.3. Product Benchmarking
      • 8.4.16.4. Recent Developments/ Strategic Initiatives
    • 8.4.17. Quantel
      • 8.4.17.1. Participant's Overview
      • 8.4.17.2. Financial Performance
      • 8.4.17.3. Product Benchmarking
      • 8.4.17.4. Recent Developments/ Strategic Initiatives